BACKGROUND: In men with metastatic castration-resistant prostate cancer (CRPC), the association of measurable tumor responses with overall survival (OS) is unknown. The authors retrospectively evaluated the TAX327 phase 3 trial to study this relation. METHODS:Eligible patients for this analysis included those with World Health Organization (WHO)-defined measurable metastatic disease randomized to receive eitherdocetaxel or mitoxantrone. OS was estimated by using the Kaplan-Meier method, and the prognostic relation of WHO-defined radiologic response with OS was performed by using Cox proportional hazards regression. Landmark analyses evaluated survival from baseline and at 2, 3, 4, and 6 months after baseline. RESULTS:Four hundred twelve patients enrolled on the TAX327 trial had measurable tumors. Thirty-seven patients exhibited a complete or partial objective response (CR/PR, 9.0%), 116 had stable disease (SD, 28.2%), 99 had progressive disease (PD, 24%) and 160 (38.8%) did not have a after-baseline objective assessment. Partial responders demonstrated longer median OS (29.0 months) than patients with SD (22.1 months) or those with PD (10.8 months) or those who were not assessed (12.7 months). These results remained after landmark analysis. The authors found a significant association between ≥ 30% prostate-specific antigen (PSA) declines and radiologic response, with ≥ 30% PSA declines occurring in all patients with CR/PR, 79.8% of patients with SD, and 34.4% with PD. Radiologic response remained a significant but modest post-treatment prognostic factor for OS after adjusting for treatment, pain response, and ≥ 30% PSA decline (P = .009). CONCLUSIONS: In men with metastatic CRPC and measurable disease receiving chemotherapy, objective tumor response was prognostic for OS and appeared to complement PSA assessment. Cancer 2011
RCT Entities:
BACKGROUND: In men with metastatic castration-resistant prostate cancer (CRPC), the association of measurable tumor responses with overall survival (OS) is unknown. The authors retrospectively evaluated the TAX327 phase 3 trial to study this relation. METHODS: Eligible patients for this analysis included those with World Health Organization (WHO)-defined measurable metastatic disease randomized to receive either docetaxel or mitoxantrone. OS was estimated by using the Kaplan-Meier method, and the prognostic relation of WHO-defined radiologic response with OS was performed by using Cox proportional hazards regression. Landmark analyses evaluated survival from baseline and at 2, 3, 4, and 6 months after baseline. RESULTS: Four hundred twelve patients enrolled on the TAX327 trial had measurable tumors. Thirty-seven patients exhibited a complete or partial objective response (CR/PR, 9.0%), 116 had stable disease (SD, 28.2%), 99 had progressive disease (PD, 24%) and 160 (38.8%) did not have a after-baseline objective assessment. Partial responders demonstrated longer median OS (29.0 months) than patients with SD (22.1 months) or those with PD (10.8 months) or those who were not assessed (12.7 months). These results remained after landmark analysis. The authors found a significant association between ≥ 30% prostate-specific antigen (PSA)declines and radiologic response, with ≥ 30% PSAdeclines occurring in all patients with CR/PR, 79.8% of patients with SD, and 34.4% with PD. Radiologic response remained a significant but modest post-treatment prognostic factor for OS after adjusting for treatment, pain response, and ≥ 30% PSA decline (P = .009). CONCLUSIONS: In men with metastatic CRPC and measurable disease receiving chemotherapy, objective tumor response was prognostic for OS and appeared to complement PSA assessment. Cancer 2011
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Daniel P Petrylak; Donna Pauler Ankerst; Caroline S Jiang; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: J Natl Cancer Inst Date: 2006-04-19 Impact factor: 13.506
Authors: Howard I Scher; Michael J Morris; William K Kelly; Lawrence H Schwartz; Glenn Heller Journal: Clin Cancer Res Date: 2005-07-15 Impact factor: 12.531
Authors: Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Matthew S Brown; Gregory H Chu; Hyun J Kim; Martin Allen-Auerbach; Cheryce Poon; Juliette Bridges; Adria Vidovic; Bharath Ramakrishna; Judy Ho; Michael J Morris; Steven M Larson; Howard I Scher; Jonathan G Goldin Journal: Nucl Med Commun Date: 2012-04 Impact factor: 1.690
Authors: A J Zurita; D J George; N D Shore; G Liu; G Wilding; T E Hutson; M Kozloff; P Mathew; C S Harmon; S L Wang; I Chen; E Chow Maneval; C J Logothetis Journal: Ann Oncol Date: 2011-08-05 Impact factor: 32.976
Authors: Guru Sonpavde; Gregory R Pond; Melissa Plets; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Amir Goldkorn; Mark G Garzotto; Philip C Mack; Celestia S Higano; Nicholas J Vogelzang; Ian M Thompson; Przemyslaw W Twardowski; Peter J Van Veldhuizen; Neeraj Agarwal; Michael A Carducci; J Paul Monk; David I Quinn Journal: Clin Genitourin Cancer Date: 2017-05-10 Impact factor: 2.872
Authors: Andrew J Armstrong; Mario A Eisenberger; Susan Halabi; Stephane Oudard; David M Nanus; Daniel P Petrylak; A Oliver Sartor; Howard I Scher Journal: Eur Urol Date: 2011-11-12 Impact factor: 20.096
Authors: A J Armstrong; P Lin; C S Higano; C N Sternberg; G Sonpavde; B Tombal; A J Templeton; K Fizazi; D Phung; E K Wong; A Krivoshik; T M Beer Journal: Ann Oncol Date: 2018-11-01 Impact factor: 32.976
Authors: Jose Mauricio Mota; Andrew J Armstrong; Steven M Larson; Josef J Fox; Michael J Morris Journal: Prostate Cancer Prostatic Dis Date: 2019-04-29 Impact factor: 5.554
Authors: Guru Sonpavde; Ankit Madan; Mary K Baker; Jori E May; Gurudatta Naik; Sejong Bae Journal: Clin Genitourin Cancer Date: 2017-04-26 Impact factor: 2.872
Authors: Luis León-Mateos; María Vieito; Urbano Anido; Rafael López López; Laura Muinelo Romay Journal: Int J Mol Sci Date: 2016-09-20 Impact factor: 5.923
Authors: Matthew S Brown; Grace Hyun J Kim; Gregory H Chu; Bharath Ramakrishna; Martin Allen-Auerbach; Cheryce P Fischer; Benjamin Levine; Pawan K Gupta; Christiaan W Schiepers; Jonathan G Goldin Journal: J Med Imaging (Bellingham) Date: 2018-01-11
Authors: Luis León-Mateos; Helena Casas; Alicia Abalo; María Vieito; Manuel Abreu; Urbano Anido; Antonio Gómez-Tato; Rafael López; Miguel Abal; Laura Muinelo-Romay Journal: Oncotarget Date: 2017-05-19